Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Dijon – page 67

819 clinical trials in Dijon, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Dijon at a glance
819
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

819 trials in Dijon

Open in trial search

Neoplasm malignant

Not recruiting

Study on the Safety and Effectiveness of REGN7075 and Cemiplimab, with or without Chemotherapy, for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Giant cell arteritis

Not recruiting

Study on Stopping Tocilizumab for Patients with Giant Cell Arteritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Hodgkin's disease

Not recruiting

Study of Pembrolizumab and Chemotherapy for Patients with Newly Diagnosed Classical Hodgkin Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin
  • Sponsor:Merck Sharp & Dohme LLC

Diffuse large B-cell lymphoma

Not recruiting

Study Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Kite Pharma Inc.

Microsatellite instability cancer+1

Not recruiting

Study Comparing MK-1308A and Pembrolizumab for Patients with Advanced Colorectal Cancer with High Microsatellite Instability or Mismatch Repair Deficiency

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Diabetes mellitus

Not recruiting

A Study of Long-Term Safety of Teplizumab in Children and Adolescents with Recently Diagnosed Type 1 Diabetes

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Teplizumab
  • Sponsor:Provention Bio Inc.

Secondary progressive multiple sclerosis

Not recruiting

Study on Stopping Disease-Modifying Therapies in Inactive Secondary Progressive Multiple Sclerosis Patients Over 50 Using Glatiramer Acetate and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Centre Hospitalier Universitaire De Rennes

Colon cancer

Not recruiting

Comparison of drug combinations containing irinotecan, oxaliplatin, fluorouracil and folinic acid for treatment of high-risk stage III colon cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Unicancer

Ovarian cancer+1

Not recruiting

Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:MPS-102
  • Sponsor:Arcagy Gineco

Mucous membrane pemphigoid

Not recruiting

Study on Rituximab and Cyclophosphamide for Patients with Severe Mucous Membrane Pemphigoid

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glucose
  • Sponsor:Centre Hospitalier Universitaire Rouen

Hormone receptor positive breast cancer

Not recruiting

Study on the Effects of Durvalumab, Oleclumab, and Chemotherapy in Patients with Luminal B Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Institut Jules Bordet

Sarcoma

Not recruiting

Study on the Effectiveness of Nivolumab, Ipilimumab, and Pazopanib in Patients with Advanced Rare Sarcomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Centre Leon Berard

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Dijon

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for head and neck cancer, gastric cancer, and multiple types of lung cancer. Research encompasses novel therapeutic approaches and targeted treatments.

  • Head & Neck Squamous Cell Carcinoma
  • Pancreatic Ductal Adenocarcinoma
  • Non-Small Cell Lung Cancer

Several studies are evaluating new combination therapies and immunotherapy approaches for better treatment outcomes.

02 Immunology & Infectious Diseases

Research focusing on immune system responses and vaccine development, with particular emphasis on COVID-19 prevention and treatment strategies. Studies include innovative approaches to boosting immunity.

  • COVID-19 Vaccine Development
  • Immune System Enhancement
  • Preventive Medicine

Trials are investigating both intranasal and traditional vaccination methods for optimal immune response.

03 Cardiovascular Medicine

Studies focusing on heart disease management and prevention, including innovative treatments for acute myocardial infarction and heart failure prevention strategies.

  • Acute Myocardial Infarction
  • Heart Failure Prevention
  • Pain Management in Cardiac Conditions

Research includes novel pain management approaches and preventive treatments for cardiac conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.